HERON THERAPEUTICS, INC. /DE/
8-K
June 25, 2026
Key Highlights
- Active commercial portfolio featuring ZYNRELEF, CINVANTI, and SUSTOL
- Focus on high-growth oncology and pain management therapeutic markets
- Clear 180-day regulatory runway to regain Nasdaq compliance
Read Analysis
🤖 AI Generated